Drug intelligence / Profile preview

modified si ni san

Development stage: Unknown
Lead developer: Xi'an Hospital of Traditional Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

Modified Si Ni San is a Traditional Chinese Medicine (TCM) formulation being investigated by the Xi'an Hospital of Traditional Chinese Medicine for post-polypectomy management in patients with colorectal polyps. Based on the classic Si Ni San formula, this modified version is designed to regulate the gut microbiota and reduce systemic inflammation. Clinical evaluation focuses on its ability to alter microbial diversity and composition (measured via 16S rRNA sequencing) and decrease levels of pro-inflammatory cytokines, specifically Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α). The primary therapeutic goal is to restore intestinal homeostasis and reduce the risk of polyp recurrence following colonoscopic removal.

Other names: Modified Si-Ni-San

Beyond the preview

Go deeper on modified si ni san.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on modified si ni san.

Explore the full profile